Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab

D Daniel; V Kuchava; I Bondarenko; O Ivashchuk; D Spigel; A Dasgupta; S Reddy; T Melkadze; J Jaal; I Kudaba; L Hart; A Matitashvili; KD Koynov; Z Yang; SG Wolfe; R Malik; SR Morris; JM Antal; J Goldschmidt

Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab

D Daniel, V Kuchava, I Bondarenko, O Ivashchuk, D Spigel, A Dasgupta, S Reddy, T Melkadze, J Jaal, I Kudaba, L Hart, A Matitashvili, KD Koynov, Z Yang, SG Wolfe, R Malik, SR Morris, JM Antal, J Goldschmidt

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	713
Number of pages	1
Journal	Annals of Oncology
Volume	30
Issue number	Suppl.5
Publication status	Published - Oct 2019
Externally published	Yes
Event	European Society of Medical Oncology (ESMO) Congress - Barcelona, Spain Duration: 27 Sept 2019 → 1 Oct 2019 Conference number: 44 https://www.esmo.org/meetings/past-meetings/esmo-congress-2019

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1093/annonc/mdz264.006

Cite this

Daniel, D., Kuchava, V., Bondarenko, I., Ivashchuk, O., Spigel, D., Dasgupta, A., Reddy, S., Melkadze, T., Jaal, J., Kudaba, I., Hart, L., Matitashvili, A., Koynov, KD., Yang, Z., Wolfe, SG., Malik, R., Morris, SR., Antal, JM., & Goldschmidt, J. (2019). Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab. Annals of Oncology, 30(Suppl.5), 713. https://doi.org/10.1093/annonc/mdz264.006

@article{57d85355e7304be590e4b43a86d0af0a,

title = "Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab",

author = "D Daniel and V Kuchava and I Bondarenko and O Ivashchuk and D Spigel and A Dasgupta and S Reddy and T Melkadze and J Jaal and I Kudaba and L Hart and A Matitashvili and KD Koynov and Z Yang and SG Wolfe and R Malik and SR Morris and JM Antal and J Goldschmidt",

year = "2019",

month = oct,

language = "English",

volume = "30",

pages = "713",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "Suppl.5",

note = "European Society of Medical Oncology (ESMO) Congress, ESMO 2019 ; Conference date: 27-09-2019 Through 01-10-2019",

url = "https://www.esmo.org/meetings/past-meetings/esmo-congress-2019",

}

Daniel, D, Kuchava, V, Bondarenko, I, Ivashchuk, O, Spigel, D, Dasgupta, A, Reddy, S, Melkadze, T, Jaal, J, Kudaba, I, Hart, L, Matitashvili, A, Koynov, KD, Yang, Z, Wolfe, SG, Malik, R, Morris, SR, Antal, JM & Goldschmidt, J 2019, 'Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab', Annals of Oncology, vol. 30, no. Suppl.5, pp. 713. <https://doi.org/10.1093/annonc/mdz264.006>

TY - JOUR

T1 - Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab

AU - Daniel, D

AU - Kuchava, V

AU - Bondarenko, I

AU - Ivashchuk, O

AU - Spigel, D

AU - Dasgupta, A

AU - Reddy, S

AU - Melkadze, T

AU - Jaal, J

AU - Kudaba, I

AU - Hart, L

AU - Matitashvili, A

AU - Koynov, KD

AU - Yang, Z

AU - Wolfe, SG

AU - Malik, R

AU - Morris, SR

AU - Antal, JM

AU - Goldschmidt, J

N1 - Conference code: 44

PY - 2019/10

Y1 - 2019/10

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/WOS:000491295505014

M3 - Meeting Abstract

SN - 0923-7534

VL - 30

SP - 713

JO - Annals of Oncology

JF - Annals of Oncology

IS - Suppl.5

T2 - European Society of Medical Oncology (ESMO) Congress

Y2 - 27 September 2019 through 1 October 2019

ER -

Trilaciclib (T) decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Cite this